Avid Bioservices Inc (CDMO)

[biopharm]

You want to get access to the latest and greatest treatment for advanced NSCLC to extend your survival time so you ask your Dr. whether you should start taking Opdivo or go into the Sunrise trial. If your Dr. has heard SK speak at a visit to this trial site or at one of the many preclinical Bavi data dumps (including AACR tomorrow) then he is likely to answer the question this way: If you enter the Sunrise trial you have a 50% chance of being in the treatment arm and there is very strong evidence that Bavituximab will trigger an immune response that will increase your survival time substantially with very manageable sided effects. If you start an Opdivo regimen you have a 70% chance it won’t work for you and you have a good chance of experiencing serious side effects that we may be able to manage but we don’t understand these immune system side effects as well as we understand chemo side effects.

Fire Fox, very interesting post. Dr. Rolf Stahel made a statement and I honestly think it is because IO is one of the very, very few paradigm shifts that is still causing a bit of stir crazy Big Pharmas to go in circles and wondering what to do...

Rolf Stahel = President of ESMO

"Immuno-Oncology for most of the part is clinical trials, but there have been agents - immune checkpoint inhibitors that have regulatory approval for clinical use. The thing is though, the results are...good, but there is so much more hope for better results that I would think that most of the physicians or centers that deal with Immuno-Oncology would like to treat the patient in trials to give him an even better chance than what is already available"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112876671